Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
0.00%
)
US TECH 100
22,785.60
(
-0.72%
)
Dow Jones
45,960.11
(
0.00%
)
Brent Oil
104.60
(
3.90%
)
Bitcoin
66,511.00
(
-3.31%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 856

Thursday, 01/22/2004 12:11:14 PM

Thursday, January 22, 2004 12:11:14 PM

Post# of 257295
Lucentis update from today’s Novartis CC:

The first release of data from the two phase-3 Lucentis trials is not planned until 2006.

As discussed in #856, Lucentis patients will be treated for two years, even though the primary endpoint in the trials is visual acuity at one year.

--
P.S. drbio: NVS has begun phase-3 patient enrollment in LAF237.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today